JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Vaxart Inc

Închisă

0.32

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

Indicatori cheie

By Trading Economics

Venit

-3.6M

-16M

Vânzări

5.7M

21M

Marjă de profit

-74.684

Angajați

105

EBITDA

-3.6M

-12M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+1566.67% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

3.4M

96M

Deschiderea anterioară

0.32

Închiderea anterioară

0.32

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Vaxart Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2025, 21:42 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 aug. 2025, 21:21 UTC

Câștiguri
Principalele dinamici ale pieței

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug. 2025, 20:45 UTC

Câștiguri

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 aug. 2025, 19:15 UTC

Principalele dinamici ale pieței

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 aug. 2025, 21:30 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 21:21 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 aug. 2025, 21:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss $938M >RIG

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss/Shr $1.06 >RIG

4 aug. 2025, 20:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 aug. 2025, 20:15 UTC

Câștiguri

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 aug. 2025, 20:13 UTC

Câștiguri

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 aug. 2025, 20:09 UTC

Câștiguri

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 aug. 2025, 20:06 UTC

Câștiguri

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparație

Modificare preț

Vaxart Inc Așteptări

Obiectiv de preț

By TipRanks

1566.67% sus

Prognoză pe 12 luni

Medie 6 USD  1566.67%

Maxim 8 USD

Minim 4 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVaxart Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.4007 / 0.4252Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.